Phase I open-label, dose escalation trial of VSV-GP monotherapy and in combination with ezabenlimab in patients with advanced or metastatic solid tumors (NCT05155332)
AE, adverse event, BOR, best objective response; cRP2D, combination recommended phase 2 dose; DLT, dose-limiting toxicity; ECOG PS, Eastern Cooperative Oncology Group performance status; GP, glycoprotein; i.t., intratumoral; itCR, intratumoral immunotherapy confirmed response; itPR, intratumoral immunotherapy partial response; itRECIST, Response Criteria for Intratumoral Immunotherapy in Solid Tumors; i.v., intravenous; mRP2D, monotherapy recommended phase 2 dose; MTD, maximum tolerated dose; VSV, vesicular stomatitis virus.